Vascular endothelial growth factor up-regulation via p21-activated kinase-1 signaling regulates heregulin-β1-mediated angiogenesis

被引:104
作者
Bagheri-Yarmand, R [1 ]
Vadlamudi, RK [1 ]
Wang, RA [1 ]
Mendelsohn, J [1 ]
Kumar, R [1 ]
机构
[1] Univ Texas, MD Anderson Canc Ctr 108, Dept Mol & Cellular Oncol, Houston, TX 77030 USA
关键词
D O I
10.1074/jbc.M006150200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Heregulin-beta1 promotes the activation of p21-activated kinase 1 (Pak1) and the motility and invasiveness of breast cancer cells. In this study, we identified vascular endothelial growth factor (VEGF) as a gene product induced by heregulin-beta1, The stimulation by heregulin-beta1 of breast cancer epithelial cells induced the expression of the VEGF mRNA and protein and its promoter activity. Heregulin-beta1 also stimulated angiogenesis in a VEGF-dependent manner. Herceptin, an anti-HER2 antibody inhibited heregulin-beta1-mediated stimulation of both VEGF expression in epithelial cells and angiogenesis in endothelial cells. Because the activation of Pak1 and VEGF expression are positively regulated by heregulin-beta1, we hypothesized that Pak1 regulates VEGF expression, and hence explored the role of Pak1 in angiogenesis,We provide new evidence to implicate Pak1 signaling in VEGF expression. Overexpression of a kinase-dead K299R Pak1 leads to suppression of VEGF promoter activity, as well as VEGF mRNA expression and secretion of VEGF protein. Conversely, kinase-active T423E Pak1 promotes the expression and secretion of VEGF. Furthermore, expression of the heregulin-beta1 transgene, HRG, in harderian tumors in mice enhances the activation of Pak1 as well as expression of VEGF and angiogenic marker CD34 antigen. These results suggest that heregulin-beta1 regulates angiogenesis via up-regulation of VEGF expression and that Pak1 plays an important role in controlling VEGF expression and, consequently, VEGF secretion and function.
引用
收藏
页码:39451 / 39457
页数:7
相关论文
共 35 条
  • [1] Regulation of microfilament reorganization and invasiveness of breast cancer cells by kinase dead p21-activated kinase-1
    Adam, L
    Vadlamudi, R
    Mandal, M
    Chernoff, J
    Kumar, R
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (16) : 12041 - 12050
  • [2] Heregulin regulates cytoskeletal reorganization and cell migration through the p21-activated kinase-1 via phosphatidylinositol-3 kinase
    Adam, L
    Vadlamudi, R
    Kondapaka, SB
    Chernoff, J
    Mendelsohn, J
    Kumar, R
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (43) : 28238 - 28246
  • [3] Biologic effects of heregulin/neu differentiation factor on normal and malignant human breast and ovarian epithelial cells
    Aguilar, Z
    Akita, RW
    Finn, RS
    Ramos, BL
    Pegram, MD
    Kabbinavar, FF
    Pietras, RJ
    Pisacane, P
    Sliwkowski, MX
    Slamon, DJ
    [J]. ONCOGENE, 1999, 18 (44) : 6050 - 6062
  • [4] The ErbB signaling network in embryogenesis and oncogenesis: Signal diversification through combinatorial ligand-receptor interactions
    Alroy, I
    Yarden, Y
    [J]. FEBS LETTERS, 1997, 410 (01) : 83 - 86
  • [5] Bagheri-Yarmand R, 1999, CANCER RES, V59, P507
  • [6] An immunological approach reveals biological differences between the two NDF/heregulin receptors, ErbB-3 and ErbB4
    Chen, XM
    Levkowitz, G
    Tzahar, E
    Karunagaran, D
    Lavi, S
    BenBaruch, N
    Leitner, O
    Ratzkin, BJ
    Bacus, SS
    Yarden, Y
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (13) : 7620 - 7629
  • [7] DVORAK HF, 1995, AM J PATHOL, V146, P1029
  • [8] MODULATION OF THE ORGAN MICROENVIRONMENT FOR TREATMENT OF CANCER METASTASIS
    FIDLER, IJ
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1995, 87 (21) : 1588 - 1592
  • [9] FINA L, 1990, BLOOD, V75, P2417
  • [10] ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling
    GrausPorta, D
    Beerli, RR
    Daly, JM
    Hynes, NE
    [J]. EMBO JOURNAL, 1997, 16 (07) : 1647 - 1655